Glenmark Life Sciences Limited Share Price

Equities

GLS

INE03Q201024

Pharmaceuticals

End-of-day quote NSE India S.E. 03:30:00 14/06/2024 am IST 5-day change 1st Jan Change
853.4 INR -0.55% Intraday chart for Glenmark Life Sciences Limited -1.65% +29.88%
Sales 2024 22.83B 273M Sales 2025 * 25.67B 307M Capitalization 105B 1.25B
Net income 2024 4.71B 56.38M Net income 2025 * 5.47B 65.45M EV / Sales 2024 4.04 x
Net cash position 2024 3.02B 36.11M Net cash position 2025 * 2.5B 29.95M EV / Sales 2025 * 3.98 x
P/E ratio 2024
20.2 x
P/E ratio 2025 *
19.1 x
Employees 1,824
Yield 2024
2.9%
Yield 2025 *
2.58%
Free-Float 15.72%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.55%
1 week-1.65%
Current month+2.04%
1 month+3.91%
3 months+15.42%
6 months+34.64%
Current year+29.88%
More quotes
1 week
850.00
Extreme 850
882.00
1 month
755.95
Extreme 755.95
882.00
Current year
655.65
Extreme 655.65
906.00
1 year
555.85
Extreme 555.85
906.00
3 years
370.00
Extreme 370
906.00
5 years
370.00
Extreme 370
906.00
10 years
370.00
Extreme 370
906.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 58 13/19/13
Director of Finance/CFO - 01/22/01
Compliance Officer - 23/21/23
Members of the board TitleAgeSince
Director/Board Member 66 30/20/30
Chief Executive Officer 58 13/19/13
Human Resources Officer 49 11/18/11
More insiders
Date Price Change Volume
14/24/14 853.4 -0.55% 49,189
13/24/13 858.1 -0.68% 47,853
12/24/12 864 -0.33% 60,649
11/24/11 866.8 -1.10% 59,972
10/24/10 876.5 +1.01% 62,998

End-of-day quote NSE India S.E., June 14, 2024

More quotes
Glenmark Life Sciences Limited is an India-based developer and manufacturer of non-commoditized, active pharmaceutical ingredients (APIs) in chronic therapeutic areas. The Company is providing contract development and manufacturing (CDMO) services to a range of multinational and specialty pharmaceutical companies. Its primary therapy areas include cardiovascular (CVS) disease, central nervous system (CNS) disorders, diabetes, oncology, pain management (anti-migraine, analgesic) and anti-infectives (antibiotic). It also develops APIs in the therapeutic areas such as anti-fungal, anti-histaminic, anti-acne, anti-emetic, ophthalmologic agent, urinary and anti-spasmodic. It has a diversified portfolio of around 151 molecules & supplies its products to customers in India, Europe, North America, Latin America, Japan and the rest of the world. Its four manufacturing facilities are located in Ankleshwar, Dahej, Mohol and Kurkumbh with a total installed capacity of approximately 1198 KL.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
853.4 INR
Average target price
932.6 INR
Spread / Average Target
+9.29%
Consensus

Quarterly revenue - Rate of surprise